Trump's Drug-Price Order May Have Little Impact on Drugmakers -- Market Talk
Dow Jones
May 13
1258 ET - President Trump's executive order aimed at lowering the cost of prescription drugs might make drugmakers' stocks more volatile in the near term, but probably won't damage their healthy long-term prospects, Gabelli Funds portfolio manager Jeff Jonas says in a note. He's skeptical that the order's mandates will ever happen, and thinks it would be hard to get Europe to raise their prices given their tight budget situations and defense spending needs, Jonas says. The order does put negative pressure on pharmacy benefits managers such as Cigna Group, CVS Health and UnitedHealth Group, Jonas says. (dean.seal@wsj.com)
(END) Dow Jones Newswires
May 12, 2025 12:58 ET (16:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.